CADL ▼ -0.3% - Candel Therapeutics, Inc.
$CADL - Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
01-OCT-2026 08:05 AM ET
Share this post
More filings for $CADL
CADL ▲ +1.9% - Candel Therapeutics, Inc.Oct 2, 2026CADL ▼ -2.6% - Candel Therapeutics, Inc.Oct 1, 2026CADL ▲ +0.6% - Candel Therapeutics, Inc.Sep 30, 2026CADL ▲ +0.6% - Candel Therapeutics, Inc.Sep 30, 2026CADL ▲ +1.1% - Candel Therapeutics, Inc.Sep 10, 2026CADL ▼ -2.2% - Candel Therapeutics, Inc.Sep 1, 2026
View full $CADL filing history →💬 Comments
Loading comments…
Leave a comment